TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00597857
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
Study: NCT00597857
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: receipt of a placebo pill for 16 days
Study: NCT00819091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1356 5mg one tablet daily
Study: NCT00972075
Drug: melatonin (Circadin)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
Study: NCT00972075
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet per day 2 hours before going to bed
Study: NCT03977792
Drug: BOR15001L7
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
Study: NCT02097394
Drug: Combizym
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combizym( 1 tablet, po, tid)
Study: NCT00141453
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT02252042
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle
Study: NCT02355925
Drug: intrauterine injection of uhCG
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
Study: NCT02355925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
Study: NCT02404038
Drug: Nur-Isterate
Normalized name: Glyceryl Distearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
Study: NCT02818309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02345174
Drug: GSK2849330
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
Study: NCT01725906
Drug: empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14
Study: NCT01725906
Drug: Genotypic resistance guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14
Study: NCT00400777
Drug: Valsartan, hydrochlorothiazide and amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00391898
Drug: Levodopa/carbidopa/entacapone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
Study: NCT00391898
Drug: Levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
Study: NCT02404038
Drug: Triphasil
Normalized name: Triphasil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert
Study: NCT01711333
Drug: Pletaal SR capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: two capsules once a day of Pletaal SR 100mg Capsules
Study: NCT04207944
Drug: Sulindac 400 MG
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
Study: NCT03710291
Drug: TRC101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, non-absorbed, polymeric hydrochloric acid binder
Study: NCT03710291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01766401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01766401
Drug: Vilazadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viibryd
Study: NCT01020994
Drug: LAS41003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, topically
Study: NCT01020994
Drug: LAS189962
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, topically
Study: NCT01020994
Drug: LAS189961
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, topically
Study: NCT04430036
Drug: AGEN1884
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fully human monoclonal Anti-PD-1 Antibody
Study: NCT04430036
Drug: AGEN2034
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fully human monoclonal Anti-PD-1 Antibody
Study: NCT00642824
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
Study: NCT01614951
Drug: HTK Custodiol
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmoplegia before ECC.
Study: NCT02755259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02442765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06178835
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
Study: NCT00003958
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05536934
Drug: Nω-hydroxy-nor-arginine
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00910104
Drug: Omegaven®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
Study: NCT02546999
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The agent will be given only once at point zero in the time scheme for the project.
Study: NCT00755521
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg
Study: NCT04971759
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levobupivacaine 5% + 1µg/kg fentanyl
Study: NCT01984294
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
Study: NCT04335357
Drug: TBR-760
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
Study: NCT04335357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02376790
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.
Study: NCT02376790
Drug: Placebo to Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to methotrexate capsules taken orally once a week.
Study: NCT02542657
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00044564
Drug: Bay 59-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
Study: NCT02641938
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
Study: NCT03995147
Drug: R-CHOP Protocol
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
Study: NCT03562884
Drug: BLI800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
Study: NCT03643900
Drug: rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: rectal indomethacin 100mg at preoperative 30min
Study: NCT02407808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
Study: NCT02182336
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: days 1, 10 and 19
Study: NCT00004257
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02238483
Drug: AZD7624 1.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled AZD7624 solution, 11 mg/mL
Study: NCT02238483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo solution
Study: NCT03392896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
Study: NCT02574455
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
Study: NCT00099801
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01389895
Drug: AMG 557 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
Study: NCT02965846
Drug: AGN-195263
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-195263 will be instilled in each eye twice daily.
Study: NCT02965846
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
Study: NCT00606021
Drug: Best Supportive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Study: NCT02058875
Drug: Myfortic®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02058875
Drug: Neoral®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02058875
Drug: Cellcept®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02777008
Drug: Placebo for CTP-543
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03152175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg / kg of matched placebo, oral capsule
Study: NCT02067104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
Study: NCT00677391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, once daily
Study: NCT00462358
Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Study: NCT01594489
Drug: Hydration plus N-acetylcisteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI
Study: NCT01431794
Drug: LDE225-600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days.
Study: NCT01431794
Drug: LDE225-400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: oral LDE225 (Sonidegib), 400mg daily.
Study: NCT01431794
Drug: LDE225-800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: oral LDE225 (Sonidegib), 800mg daily.
Study: NCT03735537
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Any brand or preparation may be used to deliver the required dose of 5mg
Study: NCT01134328
Drug: AC-150 Combo
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye for up to 14 days
Study: NCT01134328
Drug: AC-150A 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye once per day for up to 14 days
Study: NCT01497665
Drug: GRN1005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg/m2 IV every 3 weeks
Study: NCT01692184
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03066115
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description.
Study: NCT03066115
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description.
Study: NCT00380939
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01101217
Drug: Zinc Supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
Study: NCT01101217
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo daily for 6 weeks
Study: NCT00976495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, 12 weeks
Study: NCT02418572
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)
Study: NCT02418572
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG
Study: NCT04405921
Drug: Azithromycin 250 MG
Normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally or via gastric tube
Study: NCT00092300
Drug: MK0966, rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092300
Drug: Comparator: valdecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04073953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Study: NCT02256254
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 Simvastatin capsules of 20 mg every evening for 14 days
Study: NCT02256254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules every evening for 14 days
Study: NCT01122641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched tablets
Study: NCT00738023
Drug: Normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
Study: NCT04678193
Drug: Coromec Registry with ECL-19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
Study: NCT01226602
Drug: AZD6140
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2Y12 receptor antagonist
Study: NCT01226602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03024151
Drug: Comthyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: T4/T3 combination replacement
Study: NCT02132169
Drug: Drug: AC-170 0.24%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00686699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT00736385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 2000 mg daily for 12 months
Study: NCT03276494
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous administration of hypertonic saline
Study: NCT02411994
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04065295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT01231802
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17
Study: NCT03020797
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03760562
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucocorticoids.
Study: NCT01231802
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
Study: NCT02283242
Drug: Placebo (for galantamine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use for 12 weeks
Study: NCT00886756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01064518
Drug: Placebo (Dose B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
Study: NCT03601091
Drug: Precedex 200 MCG in 2 ML Injection
Normalized name: Precedex 200 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy of the drug
Study: NCT03988842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution reconstituted to mimic Alteplase 50mg vial
Study: NCT01837927
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 52 weeks